Jacob Christ1, Christopher N Herndon1, Bo Yu2. 1. Department of Obstetrics and Gynecology, University of Washington, 1959 NE Pacific St, Seattle, WA, 98195, USA. 2. Department of Obstetrics and Gynecology, University of Washington, 1959 NE Pacific St, Seattle, WA, 98195, USA. boyumich2@gmail.com.
Abstract
PURPOSE: To report three cases of severe ovarian hyperstimulation syndrome (OHSS) among oncofertility patients receiving a long-acting GnRH agonist for ovarian suppression after controlled ovarian hyperstimulation (COH) with a GnRH antagonist protocol METHODS: Chart abstraction was completed for three patients at a single academic medical center. Patients included were undergoing fertility preservation prior to gonadotoxic chemotherapy. All patients underwent COH with GnRH antagonist protocol and embryo cryopreservation immediately followed by ovarian suppression with long-acting GnRH agonist. Main outcome measure was development of OHSS. RESULTS: Despite using GnRH agonist trigger and freezing all embryos, patients developed ascites, intermittent hyponatremia and hemoconcentration consistent with severe early-onset OHSS after receiving long-acting GnRH agonist immediately following oocyte retrieval for ovarian preservation. CONCLUSIONS: Risk of severe OHSS may be increased when a long-acting GnRH agonist is used for ovarian suppression immediately following oocyte retrieval. A delay in initiating long-acting GnRH agonist after oocyte retrieval in patients at high risk for developing OHSS should be considered.
PURPOSE: To report three cases of severe ovarian hyperstimulation syndrome (OHSS) among oncofertility patients receiving a long-acting GnRH agonist for ovarian suppression after controlled ovarian hyperstimulation (COH) with a GnRH antagonist protocol METHODS: Chart abstraction was completed for three patients at a single academic medical center. Patients included were undergoing fertility preservation prior to gonadotoxic chemotherapy. All patients underwent COH with GnRH antagonist protocol and embryo cryopreservation immediately followed by ovarian suppression with long-acting GnRH agonist. Main outcome measure was development of OHSS. RESULTS: Despite using GnRH agonist trigger and freezing all embryos, patients developed ascites, intermittent hyponatremia and hemoconcentration consistent with severe early-onset OHSS after receiving long-acting GnRH agonist immediately following oocyte retrieval for ovarian preservation. CONCLUSIONS: Risk of severe OHSS may be increased when a long-acting GnRH agonist is used for ovarian suppression immediately following oocyte retrieval. A delay in initiating long-acting GnRH agonist after oocyte retrieval in patients at high risk for developing OHSS should be considered.
Authors: B C Fauser; D de Jong; F Olivennes; H Wramsby; C Tay; J Itskovitz-Eldor; H G van Hooren Journal: J Clin Endocrinol Metab Date: 2002-02 Impact factor: 5.958
Authors: Human Mousavi Fatemi; Biljana Popovic-Todorovic; Peter Humaidan; Shahar Kol; Manish Banker; Paul Devroey; Juan Antonio García-Velasco Journal: Fertil Steril Date: 2014-02-15 Impact factor: 7.329
Authors: Sadia Shakeel; Wajiha Iffat; Ambreen Qamar; Shagufta Nesar; Fareeha Butt; Sobia Naseem Siddiqui; Hina Rehman; Anees Ur Rehman Journal: Front Public Health Date: 2022-03-24